Abstract

Haemonetics will release fiscal Q3 2026 results on February 05, 2026, Pre-Market; this preview summarizes last quarter’s performance and current-quarter expectations, including revenue, margins, adjusted EPS, segment dynamics, and prevailing analyst views gathered through January 29, 2026.

Market Forecast

Consensus and company-indicated projections point to fiscal Q3 2026 revenue of USD 331.62 million, adjusted EPS of USD 1.25, and EBIT of USD 88.75 million; year-over-year, revenue is expected to decline by 6.04%, EPS to rise by 6.84%, and EBIT to grow by 3.76%. The main business outlook highlights stable hospital products and services demand and resilient plasma product revenue trends, with gross profit margin and net profit margin not formally guided but implied steady on recent performance. The segment with the most promising traction is hospital products and services, which generated USD 145.50 million last quarter with solid share within the mix; plasma products and services delivered USD 125.36 million and continues to be supported by utilization and pricing, while blood center contributed USD 56.45 million.

Last Quarter Review

Haemonetics reported fiscal Q2 2026 revenue of USD 327.32 million, a gross profit margin of 59.45%, GAAP net profit attributable to the parent company of USD 38.68 million, a net profit margin of 11.82%, and adjusted EPS of USD 1.27, reflecting year-over-year adjusted EPS growth of 13.39% and revenue decline of 5.27%. A notable highlight was EBIT of USD 87.28 million versus expectations of USD 78.56 million, demonstrating operating leverage and disciplined expense control. Main business performance showed hospital products and services revenue of USD 145.50 million, plasma products and services revenue of USD 125.36 million, and blood center revenue of USD 56.45 million, with hospital and plasma continuing to anchor the top line while blood center stabilized.

Current Quarter Outlook

Hospital Products and Services

The hospital segment remains the largest contributor and an anchor for near-term revenue stability. Order patterns have indicated consistent procedure volumes, which tend to support disposables pull-through and drive margin accretion given the segment’s mix profile. Pricing discipline and product mix enhancements are expected to maintain gross margin resilience close to recent levels, assuming supply chain and input costs remain stable. Management’s recent cadence of execution suggests continued focus on cost efficiency, and the segment’s breadth across geographies offers diversification that tempers idiosyncratic demand swings in any single market.

Plasma Products and Services

Plasma continues to be a key strategic growth vector given collection demand and client utilization rates. The revenue run-rate last quarter at USD 125.36 million provides a base from which modest growth is achievable if throughput and contract volumes hold, even as the company’s total revenue guide implies a year-over-year decline for the quarter. The margin profile in plasma is supported by consumables economics and installed base productivity; incremental improvements in center efficiency and workflow digitization can enhance EBIT contribution. Near-term risks include any slowdown in donor traffic or timing shifts in center expansions, but pricing and long-term contracts typically soften volatility and sustain revenue visibility.

Blood Center

The blood center business, at USD 56.45 million last quarter, represents a smaller but meaningful share of the portfolio. Mix dynamics here are less margin-accretive compared with hospital and plasma, yet stable volumes provide consistent cash generation that supports corporate overhead absorption. Strategic initiatives to optimize product offerings and customer engagement may curb revenue erosion and maintain channel relevance. Given the broader portfolio’s strength, the blood center segment’s steady performance helps balance cyclical movement in other areas and contributes to a more predictable quarterly outcome.

Stock Price Drivers This Quarter

Investors will focus on the interplay between top-line resilience and margin durability, particularly how gross profit margin trends compare with the recent 59.45% level and whether net profit margin can hold near 11.82%. Adjusted EPS guidance at USD 1.25 sets a benchmark that hinges on operating expense control and execution in hospital and plasma segments. Management commentary around demand conditions, contract renewals, and supply chain efficiency will influence sentiment, while EBIT delivery close to USD 88.75 million could validate the thesis of sustained operational discipline despite a softer revenue backdrop.

Analyst Opinions

Sell-side views gathered over the past six months lean positive, with a majority expecting Haemonetics to meet or modestly exceed adjusted EPS guidance despite a year-over-year revenue decline. Notable institutional commentary emphasizes the company’s operating leverage and mix-led margin support, citing last quarter’s EBIT outperformance of USD 8.72 million versus estimates as evidence of execution consistency. The constructive stance highlights hospital products and services stability and plasma collection trends as underpinning EBIT resilience, with attention on whether gross margin holds around the recent 59.45% level and adjusted EPS prints at USD 1.25 or above. Overall, the prevailing view anticipates a balanced quarter in which margins and EPS provide support even as revenue faces discrete headwinds, with valuation sensitivity tied to management’s tone on demand sustainability and visibility into fiscal year trajectory.